NDAORALTABLETPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
INQOVI (cedazuridine and decitabine) by Taiho Oncology is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside metabolic inhibitor [epc]. First approved in 2020.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INQOVI is an oral tablet combining cedazuridine and decitabine, a nucleoside metabolic inhibitor approved in 2020 for myelodysplastic syndromes. It works by inhibiting nucleic acid synthesis to suppress abnormal hematopoietic cell proliferation. The fixed-dose combination enhances decitabine bioavailability, enabling oral administration versus intravenous dosing.
$0.077BPart D
Peak14.4 years to LOEProduct is at peak commercial performance with stable $77M spending in 2023, suggesting mature field team and established market presence without major growth trajectory.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Inqovi Maintenance Therapy in Myeloid Neoplasms
Started Sep 2021
22 enrolled
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaStem Cell Leukemia
Career Relevance
Working on INQOVI offers stability in a mature, peak-stage oncology product with 14+ years of patent protection and established market presence. Career growth focuses on deepening market penetration, managing safety/compliance complexity, and preparing for long-term LOE transition rather than launch-phase acceleration.
Brand Manager
Worked on INQOVI at Taiho Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.